Use

Neurofascin-155 IgG4 antibodies are present in approximately 4% to 18% of patients with chronic inflammatory demyelinating neuropathy (CIDP) and, more rarely, in those with more acute forms of demyelinating neuropathy. This biomarker aids in the identification of a subset of these patients who are more likely to present with distal weakness, gait disturbance, tremor, and dysarthria compared to classic CIDP. Seropositive patients often require second line treatment, including B-cell depleting therapies such as rituximab. The presence of these antibodies is highly specific to CIDP and has not been reported in other disease mimics such as hereditary neuropathies and motor neuron disease.